medigraphic.com
ISSN 1561-3011 (Electronic)

2012, Number 4

<< Back Next >>

Rev Cubana Invest Bioméd 2012; 31 (4)

Hepatobiliary manifestations in patients with chronic inflammatory bowel disease

Hano GOM, Ojeda AYT, González FL, Sánchez RYA

Language: Spanish
References: 20
Page:
PDF size: 281.98 Kb.


ABSTRACT

It is common for patients with inflammatory bowel disease to present analytical or clinical changes pointing to the presence of hepatobiliary disease. The frequency of such findings ranges between 11-49 % in ulcerous colitis and between 15-30 % in Crohn's disease. In some cases, the alterations are found when the patient is first examined, while in others they emerge during the course of the disease. An observational retrospective descriptive study was conducted of 180 patients with inflammatory bowel disease cared for at the Institute of Gastroenterology. Hepatobiliary manifestations were found in 17 patients (9.4 %): 12 with ulcerous colitis and 5 with Crohn's disease. The variables studied were sex, age, years of evolution by type of inflammatory disease, type of hepatobiliary manifestation, clinical symptoms, study of hepatic enzymes and ultrasonographic findings. There was a predominance of patients with ulcerous colitis. Female sex prevailed in ulcerous colitis. No significant differences were found in Crohn's disease. Age ranged between 30-49. The most common hepatobiliary manifestations were liver disease of unknown etiology in Crohn's disease and primary sclerosing cholangitis in ulcerous colitis. The prevailing clinical symptom in both groups was asthenia. Pruritus and jaundice were also predominant in ulcerous colitis. With respect to biochemical enzymes, there was a predominance of hypertransaminasemia. Ultrasonographically, a granular aspect and increased hepatic echogenicity were the prevailing features.


REFERENCES

  1. Jess T, Riis L, Vind I, Winther KV, Borg S, Binder V, et al. Changes in clinical characteristics, course, and prognosis of inflammatory bowel disease during the last 5 decades: a population-based study from Copenhagen, Denmark. Inflamm Bowel Dis. 2007;13:481-9.

  2. Rothfuss KS, Stange EF, Herrlinger KR. Extraintestinal manifestations and complications in inflammatory bowel diseases. World J Gastroenterol. 2006;12:4819-31.

  3. Solís Herruzo JA, Solís-Muñoz P. Manifestaciones hepatobiliares en la enfermedad inflamatoria intestinal. Rev Esp Enferm Dig. 2007 sep.;99(9):525-32.

  4. Knight C, Murray KF. Hepatobiliary Associations with inflammatory bowel disease. Expert Rev Gastroenterol Hepatol. 2009;3(6):681-91.

  5. Repiso A, Alcántara M, Muñoz-Rosas C, Rodríguez-Merlo R, Pérez-Grueso MJ, Carboles JM, et al. Extraintestinal manifestations of Crohn's disease: Prevalence and related factors. Rev Esp Enferm Dig. 2006;98:510-7.

  6. Eksteen B, Miles AE, Grant AJ, Adams DH. Lymphocyte homing in the pathogenesis of extra-intestinal manifestations of inflammatory bowel disease. Clin Med. 2004;4:173-80.

  7. Gisbert JP, Gonzalez-Lama Y, Mate J. Thiopurine-induced liver injury in patients with inflammatory bowel disease: a systematic review. Am J Gastroenterol. 2007;102(7):1518-27.

  8. Mendes FD, Levy C, Enders FB, Loftus EV Jr, Angulo P, Lindor KD. Abnormal hepatic biochemistries in patients with inflammatory bowel disease. Am J Gastroenterol. 2007;102(2):344-50.

  9. Nahon S, Cadranel JF, Chazouilleres O, Biour M, Jouannaud V, Marteau P. Liver and inflammatory bowel disease. Gastroenterol Clin Biol. 2009;33:370-81.

  10. Thukkani N, Williams JL, Sonnenberg A. Epidemiologic characteristics of patients with inflammatory bowel disease undergoing colonoscopy. Inflamm Bowel Dis. 2011;17(6):1333-7.

  11. Talwalkar JA, Lindor KD. Primary sclerosing cholangitis. Inflammatory Bowel Dis. 2005;11:62-72.

  12. Loftus EV, Harewood GC, Loftus CG, Tremaine WJ, Harmsen WS, Zinsmeister AR, et al. PSC-IBD: A unique form of inflammatory bowel disease associated with primary sclerosing cholangitis. Gut. 2005;54:91-6.

  13. Saich R, Chapman R. Primary sclerosing cholangitis, autoimmune hepatitis and overlap syndromes in inflammatory bowel disease. World J Gastroenterol. 2008;14(3):331-37.

  14. Parente F, Pastore L, Bargiggia S, Cucino C, Greco S, Molteni M, et al. Incidence and risk factors for gallstones in patients with inflammatory bowel disease: a large case-control study. Hepatology 2007;45:1267-74.

  15. Lapidus A, Akerlund JE, Einarson C. Gallbladder bile composition in patients with Crohn's disease. World J Gastroenterol. 2006;12:70-4.

  16. Williams H, Orchard T. Management of the extraintestinal manifestations of IBD. Inflamm Bowel Dis Monit. 2009;10:11-17.

  17. Lerardi E, Valle ND, Nacchiero MC, De Francesco V, Stoppino G, Panella C. Onset of liver damage after a single administration of infliximab in a patient with refractory ulcerative colitis. Clin Drug Investig. 2006;26(11):673-76.

  18. Broome U, Bergquist A. Primary sclerosing cholangitis, inflammatory bowel disease, and colon cancer. Semin Liver Dis. 2006;26(1):31-41.

  19. Gisbert JP, Luna M, González-Lama Y, Pousa ID, Velasco M, Moreno-Otero R, et al. Liver injury in inflammatory bowel disease: long-term follow-up study of 786 patients. Inflamm Bowel Dis. 2007;13:1106-14.

  20. Bargiggia S, Maconi G, Elli M, Molteni P, Ardizzone S, Parente F, et al. Sonographic prevalence of liver steatosis and biliary tract stones in patients with inflammatory bowel disease: Study of 511 subjects at a single center. J Clin Gastroenterol. 2003;36:417-20.




2020     |     www.medigraphic.com